This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee, Health Research, Inc. has demonstrated expertise in conducting biomedical research and clinical trials to advance cancer therapeutics, including through collaborations with Roswell Park Comprehensive Cancer Center. The Military Medical Research and Development program funds innovative, high-impact research to improve healthcare for military service members, veterans, and their families across a range of medical conditions, including cancer.
Generated 11/26/24, 1:44 AM